Global Health Drug Discovery Institute describes new SARS-CoV-2 3CLpro inhibitors

Feb. 27, 2023

Global Health Drug Discovery Institute (GHDDI) has presented 3C-like proteinase (3CLpro) (SARS-CoV-2) inhibitors reported to be useful for the treatment of Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 infections (COVID-19).

BioWorld Science Infection Coronavirus Patents

FDA says changes in Dexcom G6, G7 sensors constitute misbranding

BioWorld MedTech

The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures...

Today's news in brief

BioWorld

BioWorld briefs for March 28, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 28, 2025

CMV history cited in DMD liver death on Sarepta’s Elevidys

BioWorld

Wall Street was weighing the gravity of the death from acute liver failure of a patient who was treated for Duchenne muscular dystrophy (DMD) with Sarepta...

UK government abolishes NHS England

BioWorld MedTech

In a move that surprised many across the health care sector, the U.K. government decided to scrap NHS England, the body which runs the national health service...